Showing results (171-180 of 430) with videos related to
Sort By:
Pageof 43
Circulation. Heart Failure|March 26, 2013
Right ventricular function, pulmonary pressure estimation, and clinical outcomes in cardiac resynchronization therapyPatricia Campbell, Madoka Takeuchi, Mikhail Bourgoun, et al.American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.European Heart Journal|June 24, 2005
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registryKarolina E Szummer, Scott D Solomon, Eric J Velazquez, et al.JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.European Heart Journal|April 7, 2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)Colin Berry, Karen S Pieper, Harvey D White, et al.European Heart Journal|June 27, 2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT TrialGeorge V Moukarbel, James E Signorovitch, Marc A Pfeffer, et al.Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.American Heart Journal|March 29, 2008
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialRachel E Anderson, Marc A Pfeffer, Jens Jakob Thune, et al.Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.Pageof 43